Dichlorphenamide
FDA-approved product (tablet, oral), marketed as Daranide, Dichlorphenamide, Keveyis and 1 more.
- Registered studies
- 2
- Lab records
- 2
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Glaucoma
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Carbonic anhydrase inhibitors
- FDA pharmacologic class
- Carbonic Anhydrase Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA30.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae10.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis73.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
- M. tuberculosis: measured active in 2 of 2 lab records
Show the 2 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Dichlorphenamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Setmelanotide AcetateExisting use: Obesity61.5% AI-predicted activityagainst MRSANo documented evidence found
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection61.4% AI-predicted activityagainst MRSA50+ registered studies
- ItraconazoleExisting use: Aspergillosis, Blastomycosis, Candidiasis and 4 more61.2% AI-predicted activityagainst MRSA50+ registered studies
- SelpercatinibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more61.2% AI-predicted activityagainst MRSA42 registered studies
- Obeticholic AcidExisting use: Biliary liver cirrhosis, Cholangitis, Primary biliary cirrhosis60.9% AI-predicted activityagainst MRSA44 registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more60.8% AI-predicted activityagainst MRSA50+ registered studies
- Chlorhexidine GluconateExisting use: Eye infection, Gingivitis, Infection and 2 more60.8% AI-predicted activityagainst MRSALab records exist50+ registered studies
- CiclesonideExisting use: Airway obstruction, Allergic rhinitis, Asthma and 3 more60.7% AI-predicted activityagainst MRSA50+ registered studies
- IloperidoneExisting use: Psychosis, Schizophrenia60.6% AI-predicted activityagainst MRSA32 registered studies
- Ponatinib HydrochlorideExisting use: Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia and 1 more60.6% AI-predicted activityagainst MRSA50+ registered studies
- VoclosporinExisting use: Immune system disease, Lupus nephritis60.6% AI-predicted activityagainst MRSA28 registered studies
- Doxazosin MesylateExisting use: Benign prostatic hyperplasia, Hypertension, Myocardial infarction60.6% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Hyper- and Hypokalemic Periodic Paralysis Study
NCT00494507 · start 2007-06
Registered record
- Registry ID
- NCT00494507
- Conditions
- Hyperkalemic Periodic Paralysis; Hypokalemic Periodic Paralysis
- Interventions
- Dichlorphenamide (double-blind); Placebo (double-blind); Dichlorphenamide (open-label)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-06
- Completion
- 2013-05
- Enrolment
- 71
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyperkalemic Periodic Paralysis; Hypokalemic Periodic ParalysisInterventionDichlorphenamide (double-blind); Placebo (double-blind); Dichlorphenamide (open-label)PhasePhase 3Registry statusCompletedPhase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
NCT00004802 · start 1992-06
Registered record
- Registry ID
- NCT00004802
- Conditions
- Paralysis, Hyperkalemic Periodic; Hypokalemic Periodic Paralysis; Paramyotonia Congenita
- Interventions
- dichlorphenamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1992-06
- Completion
- Not recorded
- Enrolment
- 64
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionParalysis, Hyperkalemic Periodic; Hypokalemic Periodic Paralysis; Paramyotonia CongenitaInterventiondichlorphenamidePhasePhase 3Registry statusCompleted